GHB sits on a regulatory tightrope and the data reflects it. In the United States, about 15,000 people receive Xyrem each year for cataplexy, while global seizures exceed 500 kg annually with roughly 60% originating in Europe. These numbers separate medical prescribing from illicit trafficking and show how context drives the pattern.
Key Takeaways
- GHB is Schedule I federally in US since 2000, Schedule III as Xyrem.
- GHB is approved as Xyrem (sodium oxybate) for cataplexy treatment at doses of 4.5-9g/night in two divided doses, reducing cataplectic attacks by 65-75% over placebo.
- GHB, or gamma-hydroxybutyric acid, is a central nervous system depressant that binds to GHB-specific receptors in the brain, leading to sedation and euphoria at low doses (1-2g), sourced from pharmacological studies.
- GHB misuse occurs in 1-5% of club-goers in US surveys from 2000-2010, often mixed with alcohol.
- GHB acute toxicity causes bradycardia (HR drop 20-40 bpm) in 50% overdoses.
GHB use and related harm highlight the urgent need for awareness, safer practices, and better prevention.
Related reading
01 · Category
Legal Status and Epidemiology27 stats
01
GHB is Schedule I federally in US since 2000, Schedule III as Xyrem.
02
EU classifies GHB as Schedule IV narcotic, GBL as monitored chemical.
03
Australia lists GHB Schedule 9 (prohibited) except therapeutic.
04
UK Misuse of Drugs Act 1971: GHB Class B since 2003.
05
Canada CDSA Schedule I for GHB, possession up to 7y penalty.
06
Global GHB seizures: 500kg+ annually, 60% Europe (UNODC).
07
US Xyrem prescriptions: ~15,000 patients/year (2022).
08
GHB trafficking precursors GBL/1,4-B regulated under Analogue Act.
09
Lifetime prevalence US adults 12+: 0.5% (NSDUH 2019).
10
Past-year GHB use college students: 1.2% (2020).
11
DEA reports 400+ GHB diversion cases 2015-2020.
12
GHB wastewater analysis: 0.1-1 μg/L in US rave cities.
13
International treaties: GHB monitored under 1988 UN Convention.
14
Japan: GHB prescription only for narcolepsy since 2021.
15
Brazil ANVISA: GHB Schedule A3, therapeutic exceptions.
16
GHB positive drug tests military: 0.2% (2018-2022).
17
Europe past-month use: 0.3% young adults (ESPAD 2019).
18
GHB arrests US: ~500/year (NIBRS 2020).
19
Xyrem orphan drug status granted FDA 1994 for narcolepsy.
20
GHB analogues (GBL) possession illegal in 40+ countries.
21
NSDUH: GHB initiation age average 19.2 years.
22
GHB in sports: WADA prohibited, 5 positives 2010-2020.
23
Russia: GHB Schedule II narcotic.
24
GHB prevalence Australia: 1.4% lifetime 18-35yo.
25
FDA REMS for Xyrem: zero unapproved dispensing since 2010.
26
GHB EU early warning system alerts since 1995.
27
US states vary: CA felony possession >1oz GHB.
Interpretation
Legal Status and Epidemiology Interpretation
From narcolepsy medication to a notorious party drug, GHB walks a regulatory tightrope globally, controlled like heroin in some nations yet prescribed under heavy guard in others, while its shadow market persists with modest but stubborn use—truly a Jekyll and Hyde of the pharmaceutical world.
02 · Category
Medical and Therapeutic Uses28 stats
01
GHB is approved as Xyrem (sodium oxybate) for cataplexy treatment at doses of 4.5-9g/night in two divided doses, reducing cataplectic attacks by 65-75% over placebo.
02
In narcolepsy patients, Xyrem increases total sleep time by 60-90 minutes per night compared to baseline.
03
Clinical trials show Xyrem reduces daytime sleepiness (ESS score) by 5-7 points on average in responders.
04
GHB therapy for narcolepsy improves sleep architecture, boosting stage 3/4 sleep from 5% to 25% of total sleep time.
05
Sodium oxybate is indicated for excessive daytime sleepiness (EDS) in narcolepsy type 1, with 50-60% of patients achieving ≥3-point MOSS improvement.
06
In fibromyalgia trials, Xyrem at 4.5g/night reduced pain scores by 2-4 points on VAS (0-10 scale).
07
GHB has been studied for alcohol withdrawal, reducing CIWA-AR scores by 40% vs. diazepam in small RCTs.
08
Pediatric use of Xyrem in narcolepsy (7+ years) shows 70% reduction in cataplexy at 3-6g/night.
09
GHB enhances consolidation of declarative memory during slow-wave sleep in healthy volunteers.
10
In Parkinson's disease models, GHB reduces tremors by 30-50% via GABA-B agonism.
11
Xyrem REMS program reports 85% adherence in prescribed patients, minimizing diversion risks.
12
Long-term Xyrem use (12 months) maintains cataplexy reduction in 80% of narcolepsy patients without tolerance.
13
GHB investigational use for opioid withdrawal shows 50% retention rate at 1 week vs. 20% placebo.
14
In insomnia studies, GHB 25 mg/kg improves sleep efficiency from 75% to 92%.
15
Sodium oxybate reduces nocturnal enuresis in narcolepsy by 60-70% incidence.
16
GHB for Huntington's chorea decreases abnormal movements by 25% in open-label trials.
17
Xyrem bioavailability is 88% under fasting conditions, dropping to 60% with high-fat meal.
18
In major depression adjunct therapy, GHB improves HDRS scores by 8-12 points in 40% responders.
19
GHB anesthesia induction dose is 60-90 mg/kg IV, producing unconsciousness in 1-2 minutes.
20
Xyrem lowers apnea-hypopnea index by 30% in narcolepsy with comorbid OSA.
21
Therapeutic GHB plasma levels for narcolepsy are 50-150 μg/mL at peak.
22
GHB for schizophrenia negative symptoms reduces SANS scores by 15-20% in pilot studies.
23
Elderly narcolepsy patients on Xyrem show 55% cataplexy reduction at lower doses (3g/night).
24
GHB improves quality of life (SF-36) by 10-15 points in narcolepsy after 8 weeks.
25
Xyrem discontinuation due to adverse events is 7-10% over 6 months.
26
GHB for essential tremor reduces amplitude by 40% at 30 mg/kg daily.
27
In 1990s Europe, GHB was used off-label for chronic fatigue syndrome, reporting 60% energy improvement.
28
Xyrem enhances vivid dreaming reports in 30% of narcolepsy patients.
Interpretation
Medical and Therapeutic Uses Interpretation
GHB is a veritable Swiss Army knife of the nervous system, where its one legal blade carves out better sleep for narcolepsy patients while its many experimental tools hint at a surprisingly broad, if illicitly famous, potential to mend minds, soothe tremors, and even fight addiction.
03 · Category
Pharmacological Properties30 stats
01
GHB, or gamma-hydroxybutyric acid, is a central nervous system depressant that binds to GHB-specific receptors in the brain, leading to sedation and euphoria at low doses (1-2g), sourced from pharmacological studies.
02
The bioavailability of oral GHB is nearly 100%, with peak plasma concentrations reached within 25-45 minutes post-ingestion due to rapid absorption in the gastrointestinal tract.
03
GHB has a biphasic elimination profile, with an initial rapid phase (t1/2 ≈ 0.5-1 hour) followed by a slower phase (t1/2 ≈ 2-3 hours), influenced by endogenous GHB levels.
04
At therapeutic doses (2.25-4.5g/night), GHB increases slow-wave sleep (SWS) by 20-30% and reduces nocturnal awakenings by up to 68% in narcolepsy patients.
05
GHB inhibits dopamine release in the nucleus accumbens by 40-60% at concentrations of 1-3 mM, contributing to its rewarding effects via indirect stimulation of opioid systems.
06
Endogenous GHB levels in human cerebrospinal fluid range from 10-50 ng/mL, increasing up to 340% during sleep or under stress conditions.
07
GHB is metabolized primarily by alcohol dehydrogenase and aldehyde dehydrogenase in the liver, producing succinic semialdehyde and then succinate, entering the Krebs cycle.
08
GHB exhibits dose-dependent effects: at 10-20 mg/kg, it induces mild euphoria; at 20-30 mg/kg, hypnosis; and at >50 mg/kg, coma, due to GABA-B receptor agonism.
09
Chronic GHB administration upregulates GH secretion by 1600% acutely via GHRH stimulation, but tolerance develops within weeks.
10
GHB crosses the blood-brain barrier rapidly with a transfer constant of 0.58 mL/g/min in rats, equivalent to high lipophilicity.
11
GHB potentiates GABA-A receptors indirectly, enhancing chloride influx by 25-40% at synaptic sites.
12
The volume of distribution for GHB is 0.4-0.6 L/kg, primarily distributed in total body water compartments.
13
GHB plasma protein binding is negligible (<1%), allowing free diffusion into tissues.
14
At 1-5 mM concentrations, GHB activates GHB receptors coupled to G-proteins, inhibiting adenylate cyclase by 30-50%.
15
GHB induces hyperpolarization of thalamic neurons via potassium channel activation, reducing firing rates by 70%.
16
Renal clearance of GHB is minimal (1-2 mL/min), with 5% excreted unchanged in urine.
17
GHB increases REM sleep latency by 50-100 minutes in therapeutic regimens.
18
Synergistic effects with alcohol increase GHB potency by 2-4 fold due to shared GABAergic mechanisms.
19
GHB's pKa is 4.72, existing mostly as the ionized form at physiological pH 7.4.
20
Molecular weight of GHB is 104.10 g/mol, with logP of -0.37 indicating moderate hydrophilicity.
21
GHB stimulates acetylcholine release in the hippocampus by 200-300% at low doses.
22
Tolerance to GHB's euphoric effects develops after 3-7 days of daily use, requiring 50-100% dose escalation.
23
GHB inhibits monoamine oxidase, increasing serotonin levels by 20-40%.
24
Peak growth hormone release post-GHB peaks at 60-90 minutes, with levels 5-16 fold above baseline.
25
GHB's LD50 in rats is 1.27 g/kg orally, indicating moderate acute toxicity margin.
26
GHB enantiomers show no stereoselectivity, with (R)- and (S)-GHB equipotent.
27
GHB downregulates GABA-B receptors after chronic exposure, reducing sensitivity by 30%.
28
GHB solubility in water is >1000 mg/mL at 25°C, facilitating liquid dosing.
29
GHB activates TASK-3 potassium channels at 1-10 μM, contributing to sedation.
30
Endogenous GHB synthesis from GABA via GABA-T occurs at rates of 0.1-1 nmol/g tissue/hour in brain.
Interpretation
Pharmacological Properties Interpretation
It's the ultimate chemical double agent: a molecule that can lull you into blissful sleep at one dose, yet hijack your brain's reward system at another, all while moonlighting as a naturally occurring compound your own body produces during sleep and stress.
04 · Category
Recreational Use and Abuse30 stats
01
GHB misuse occurs in 1-5% of club-goers in US surveys from 2000-2010, often mixed with alcohol.
02
GHB-related ER visits in US rose from 55 in 1994 to 5,655 in 2011 per DAWN data.
03
Street GHB doses for euphoria average 1-3g, with polydrug use in 70% of cases.
04
Dependence develops in 50% of daily users within 1-2 weeks, characterized by withdrawal seizures.
05
GHB is involved in 1-2% of sexual assaults reported in urban areas, per forensic toxicology.
06
Prevalence of lifetime GHB use among US high school seniors is 1.4% (2019 MTF).
07
GHB powder ("G-rack") purity averages 70-90%, often cut with GBL precursor.
08
Withdrawal from GHB mimics severe alcohol withdrawal, with delirium in 20-30% cases.
09
Online forums report GHB bodybuilding use for GH boost, with 10-20g daily cycles common.
10
GHB is detected in 0.5-1% of driver impairment cases in Europe (DRUID study).
11
Festival surveys show 2-4% GHB use among EDM attendees, peaking at 5am hours.
12
GHB tolerance requires dose doubling every 3-5 days in chronic recreational users.
13
25% of GHB users report blackouts lasting 1-4 hours post-dose.
14
GHB seized in US: 90% liquid form, average concentration 1g/mL.
15
Polysubstance abuse with GHB: 80% with alcohol, 40% with MDMA.
16
GHB addiction treatment seeking peaks in ages 18-25, 60% male.
17
Anecdotal reports cite GHB as "liquid ecstasy" for disinhibition at 0.5-1.5g doses.
18
GHB use in gay club scenes: 5-10% prevalence in 2000s surveys.
19
Overdose threshold for naive users is 4-6g, causing respiratory depression.
20
GHB internet vendors ship 70% as "fish tank cleaner" mislabeled GBL.
21
Chronic recreational GHB users show 30% incidence of depression/anxiety comorbidity.
22
GHB craving intensity rates 7-9/10 on VAS during withdrawal peaks.
23
Street price of GHB: $5-10 per gram in US urban markets (2020).
24
GHB facilitates sex in 60% of user reports, increasing risky behaviors.
25
Detox success for GHB dependence: 40% relapse within 30 days post-benzodiazepine taper.
26
GHB use correlates with 2-3x higher HIV risk in MSM party scenes.
27
GHB produces dose-dependent "high": relaxation (1g), euphoria (2g), incapacitation (4g).
28
GHB deaths often involve 10-20g ingestion with alcohol, per autopsy data.
29
GHB GBL conversion by users: 1mL GBL ≈ 1.65g GHB equivalent.
30
GHB is a factor in 1% of drug-induced homicides (1990-2005 US data).
Interpretation
Recreational Use and Abuse Interpretation
Despite its reputation as a party drug, GHB's statistics sketch a dangerously efficient addiction machine, swiftly trading fleeting euphoria for dependency, blackouts, and ER visits while quietly fueling public health crises from impaired driving to sexual assault.
05 · Category
Toxicity and Health Risks29 stats
01
GHB acute toxicity causes bradycardia (HR drop 20-40 bpm) in 50% overdoses.
02
Respiratory depression from GHB overdose requires ventilation in 30-40% hospital cases.
03
GHB coma (Glasgow <8) resolves spontaneously in 2-6 hours in 90% survivors.
04
Withdrawal seizures occur 1-6 hours post-last dose in 20-50% dependent users.
05
GHB elevates liver enzymes (ALT/AST 2-5x ULN) in 15% chronic users.
06
Fatal GHB levels >500 mg/L blood, synergistic with ethanol >0.1g/dL.
07
QT prolongation (>500ms) reported in 5-10% GHB overdoses with electrolytes imbalance.
08
GHB-induced amnesia affects 70% of recreational overdoses, lasting 4-12 hours.
09
Rhabdomyolysis incidence 10-20% in prolonged GHB coma cases.
10
GHB depresses consciousness: mild (1-2g), heavy (3-4g), lethal (>6g naive).
11
Hypothermia (<35°C) in 25% GHB overdoses due to hypothalamic suppression.
12
GHB withdrawal psychosis mimics DTs, with hallucinations in 15% severe cases.
13
Emesis occurs in 40-60% GHB ingestions >3g, aiding spontaneous decontamination.
14
Cerebral edema rare but fatal in 2% pediatric GHB exposures.
15
GHB cardiotoxicity: bradycardia <40 bpm in 15% adults overdosed.
16
Chronic GHB neurotoxicity shows basal ganglia lesions on MRI in 10% long-term users.
17
Aspiration pneumonia complicates 20% intubated GHB patients.
18
GHB elevates CK >1000 U/L in 30% seizures/withdrawal cases.
19
Myoclonus/clonus in 50% GHB toxicity presentations.
20
GHB blood levels 100-300 mg/L cause stupor, >1000 mg/L often fatal.
21
Encephalopathy with lactate acidosis in 5% GHB/alcohol combos.
22
GHB dependence withdrawal duration: acute 5-15 days, protracted 3-6 months.
23
Hyponatremia (<130 mEq/L) in 10% GHB fluid-overloaded patients.
24
GHB-induced pancreatitis acute in 1-2% overdoses with vomiting.
25
Dopamine dysregulation in chronic GHB users leads to parkinsonism-like symptoms in 5%.
26
GHB overdose survival 95% with supportive care, no specific antidote.
27
Tachycardia rebound (HR >120) in 30% post-GHB resolution phase.
28
GHB GBL hydrolysis produces burns if concentrated on skin (pH<2).
29
GHB US deaths: 157 reported 1990-2010, 70% polydrug.
Interpretation
Toxicity and Health Risks Interpretation
GHB is a fickle and brutal puppeteer, pulling strings on your heart, brain, and lungs with a terrifying statistical precision that promises either a swift, amnesiac nap or a prolonged, multi-system catastrophe, all while smugly reminding you there's no antidote for its chaos.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Elena Vasquez. (2026, February 13). Ghb Statistics. Gitnux. https://gitnux.org/ghb-statistics
MLA
Elena Vasquez. "Ghb Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/ghb-statistics.
Chicago
Elena Vasquez. 2026. "Ghb Statistics." Gitnux. https://gitnux.org/ghb-statistics.
Sources & references
30 datasets cited across this report · attribution is report-level